At the Medicap Pharmacy® stores, we are dedicated to providing products and services to care for your family’s wellness. One of those services is health news you can trust. Use the filters to focus on the information that is important to you, then bookmark this page to make it a regular stop anytime you’re online.
Yervoy Gets a New Use
A medication previously approved to treat melanoma that cannot be removed by surgery just got the approval it needed for another melanoma-related use.
Novel Melanoma Lesion Rx Is a Go
There's a new, first-of-its kind treatment for the deadliest type of skin cancer.
Surgery Offers Hope for Melanoma Metastasis
In the past, melanoma that metastasized (or spread) to the abdominal organs was considered incurable. Today, surgery may be a promising treatment option.
Sunglasses: Looking Cooler and Staying Healthier
Sunglasses can do more than make you look like a movie star — they can also help protect your eyes from the sun's harmful rays.
Indoor Tanning Fades, but Millions Still Risk It
At one time, many people thought indoor tanning meant a healthy glow year-round. Today, more and more people may be realizing that this isn’t so.
ED Rx: A Possible Downside
While medications for erectile dysfunction can improve men's lives, they may also carry a downside.
Melanoma Rates on the Rise
After a long winter, you may be itching to head to the pool and bake in the sun. But don't grab your towel and sunglasses just yet. You may want to stay aware of the potential risks.
Some Skin Cancers Saw Spike
As awareness about the dangers of sun exposure and skin cancer rises, the hope is that skin cancer rates will decrease. New evidence, however, suggests that rates may not be on the decline.
Melanoma on Downswing in Kids
Parents, you can breathe a sigh of relief — the sunscreen must be working. Melanoma, an aggressive form of skin cancer, appears to be decreasing in kids.
Bristol-Myers Squibb and Lilly Colaborate to Evaluate Cancer Drug
NEW YORK & INDIANAPOLIS--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) and Eli Lilly and Company (NYSE:LLY) announced today a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb's immunotherapy Opdivo (nivolumab) in combination with Lilly's galunisertib (LY2157299).